Abstract
The introduction of serum prostate-specific antigen (PSA) testing has driven a drastic change in prostate cancer diagnosis, prognosis, and outcome monitoring over the last 2 decades. However, the widespread use of PSA testing has also generated growing concerns regarding the overdiagnosis of potentially indolent disease. Nowadays, a major current challenge for urologists is to improve the diagnosis of aggressive prostate cancer while optimizing the identification and treatment of indolent disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
